Effectiveness Of Seasonal Malaria Chemoprevention At Scale In West And Central Africa: An Observatio

The present study was conducted to explore the project, including coverage, the effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness. Researchers obtained data on the delivery, effectiveness, safety, influence on drug resistance, costs of delivery, impact on malaria incidence and mortality, and cost-effectiveness of seasonal malaria chemoprevention (SMC), during its administration for 4 months each year (2015 and 2016) to children younger than 5 years, in Burkina Faso, Chad, The Gambia, Guinea, Mali, Niger, and Nigeria in this observational study. In 2015 , they administered 12,467,933 monthly SMC treatments to a target population of 3,650,455 children, and in 2016, 25,117,480 were administered to a target population of 7,551,491. SMC at scale was found to be effective in preventing morbidity and mortality from malaria. They rarely recorded serious adverse reactions. Via door-to-door campaigns, coverage varied, with some areas consistently achieving high levels. The outcomes revealed that the markers of resistance to sulfadoxine-pyrimethamine and amodiaquine remained uncommon, but with some selection for resistance to sulfadoxine–pyrimethamine, and the situation needs to be carefully monitored. In the west and central Africa, these data should support efforts to ensure high levels of SMC coverage.

​

Source